Total Funding
70
63
Total FundingSeed raised
Growth Score 70 in past quarter
-3 pts
Heat Score 63 in past quarter
-9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
169024
EnGen Bio is a development-stage biotechnology company that pioneers a new approach to preventing and treating influenza.
- Mark Alfenito: Co-Founder, President, Manager & Chief Executive Officer
Geoffrey Yarranton: Science AdvisorPast Role: Celltech Therapeutics, Director of Research
About the Company
EnGen Bio is a development-stage biotechnology company that pioneers a new approach to preventing and treating influenza. It believes that it has identified a candidate Universal Type A Influenza vaccine. Influenza drugs and vaccines are unique because there is sufficient government funding available to develop these assets well into human
clinical trials, and possibly to market. EnGen Bio is aggressively pursuing this and similar opportunities.
It is founded in 2017 and is headquartered in Redwood City, California.
